NCT01730040
Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)
See it on ClinicalTrials.gov ↗355 people
34.9%
65.1%
124 womenmiddle line = equal numbers231 men
- Phase
- PHASE3
- Paid for by
- Regeneron Pharmaceuticals
- Finished
- 2014-05
- Health conditions
- Hypercholesterolemia
- Who could join
- Anyone
- Ages
- 18 Years – no maximum
- Average age
- mean 62.9 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
No rules that kept women out were found.
Study titles and rules are shown in their original English.